1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
TriSalus Life Sciences, Inc.

TriSalus Life Sciences, Inc.

TLSI
TriSalus Life Sciences, Inc.US flagNASDAQ Global Market
5.27
USD
-0.36
- -
324.50MMarket Cap

Total Valuation

TriSalus Life Sciences, Inc. carries a market capitalization of 324.50M, placing it among publicly traded companies globally. Its enterprise value stands at 267.82M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap324.50M
Enterprise Value267.82M

Share Statistics

TriSalus Life Sciences, Inc. currently has 61.47M shares outstanding.

Shares Outstanding61.47M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

The price-to-sales ratio is 5.04, and the price-to-book ratio stands at 42.70.

PE RatioN/A
PS Ratio5.04
PB Ratio42.70
P/TBV Ratio42.70
P/FCF Ratio-10.22
P/OCF Ratio-9.96

Enterprise Valuation

EV / Sales5.94
EV / EBITDAN/A
EV / EBITN/A
EV / FCF17.01

Financial Position

TriSalus Life Sciences, Inc. maintains a current ratio of 5.35, meaning it holds 5.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 525.59, indicating elevated leverage, while an interest coverage ratio of -5.13 demonstrates limited ability to service its debt obligations.

Current Ratio5.35
Quick Ratio4.72
Debt / Equity525.59
Debt / EBITDA-1.15
Interest Coverage-5.13

Financial Efficiency

Return on Equity (ROE)N/A
Return on Assets (ROA)-54.38
Return on Invested Capital (ROIC)N/A
Return on Capital Employed (ROCE)23.59
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover1.60

Taxes

Over the trailing twelve months, TriSalus Life Sciences, Inc. has paid 13,000.00 in income taxes, reflecting an effective tax rate of 0.26.

Income Tax13,000.00
Effective Tax Rate0.26

Stock Price Statistics

TriSalus Life Sciences, Inc.'s stock has gained approximately 15.82418% over the past 52 weeks. The 50-day moving average sits at 4.35, while the 200-day moving average is 4.79.

Beta (5Y)N/A
52-Week Price Change15.82418%
50-Day Moving Average4.35
200-Day Moving Average4.79
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, TriSalus Life Sciences, Inc. generated 45.08M in revenue and converted that into -28.21M in net income, yielding earnings per share of -0.56. EBITDA reached -29.95M, while operating income came in at -30.51M.

Revenue45.08M
Gross Profit38.67M
Operating Income-30.51M
Pretax Income-28.20M
Net Income-28.21M
EBITDA-29.95M
EBIT-30.51M
Earnings Per Share (EPS)-0.56

Balance Sheet

TriSalus Life Sciences, Inc. holds 46.29M in cash and equivalents against 34.43M in total debt, resulting in a net debt position of -13.22M. Total book value stands at 6.55M, with working capital of 48.57M providing operational flexibility.

Cash & Cash Equivalents46.29M
Total Debt34.43M
Net Debt-13.22M
Equity (Book Value)6.55M
Book Value Per Share0.11
Working Capital48.57M

Cash Flow

TriSalus Life Sciences, Inc. produced -22.80M in operating cash flow over the past twelve months. After subtracting -480,000.00 in capital expenditures, free cash flow totaled -23.28M - equivalent to -0.47 per share.

Operating Cash Flow-22.80M
Capital Expenditures-480,000.00
Free Cash Flow-23.28M
FCF Per Share-0.47

Margins

TriSalus Life Sciences, Inc. operates with a gross margin of 85.79, reflecting its pricing power and cost economics. The operating margin of -67.68 and net profit margin of -62.59 provide insight into operational efficiency.

Gross Margin85.79
Operating Margin-67.68
Pretax Margin-62.56
Profit Margin-62.59
EBITDA Margin-66.44

Dividends & Yields

Dividend Per ShareN/A
Dividend YieldN/A
Payout RatioN/A
Shareholder Yield-15.26
FCF Yield-9.79

Scores

TriSalus Life Sciences, Inc. posts an Altman Z-Score of -4.54, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score-4.54